European Antitrust Watchdogs Warn Of Uncertain Future For Pay-For-Delay Settlements
A View from Constantine Cannon’s London Office
By Irene Fraile
A recent lively discussion with European Commission competition officials indicates that antitrust enforcement is continuing to evolve to deal with the thorny issues raised by so-called “reverse-payment” or “pay-for-delay” patent litigation settlements designed to delay the sale of generic drugs.
On January 29, 2015, Brussels Matters